We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Permits Intellipharmaceutics to Skip Phase III Trials of Rexista Pain Reliever

FDA Permits Intellipharmaceutics to Skip Phase III Trials of Rexista Pain Reliever

May 28, 2015

Toronto, Canada-based Intellipharmaceutics expects to file an NDA for its opioid painkiller Rexista XR within the next year, after receiving notification from the FDA that it won’t need to conduct Phase III clinical trials.

The agency based its decision on data from three Phase I trials that showed Rexista XR (abuse-deterrent oxycodone hydrochloride) to be bioequivalent to OxyContin (oxycodone), the firm said Thursday.

The waiver is expected to save Intellipharmaceutics about $19 million, Chief Financial Officer Domenic Della Penna tells DID. Phase III trials would have cost roughly $20 million, whereas filing the NDA will cost no more than $1 million.

Rexista XR is not a generic, the company stresses. Intellipharmaceutics took advantage of the 505(b)(2) pathway, which allows it to submit an NDA for a new drug based off a reference product. In this case, the reference product is Purdue Pharma’s OxyContin, Della Penna says.

Rexista XR adds a few abuse-deterrent features that OxyContin does not, he adds, which qualifies it as a new drug. It is designed to prevent dose dumping when mixed with alcohol and immediately clumps when crushed, pulverized or hydrated.

If approved, the 505(b)(2) pathway will provide Rexista XR five years of marketing exclusivity. Should the drug make it to market, Intellipharmaceutics intends it for managing moderate to severe pain in patients who need round-the-clock analgesics. — Lena Freund

Pharmaceuticals Regulatory Affairs Research and Development

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Wandercraft Walking Robotic Exoskeleton Gets FDA Clearance for Stroke Rehab

  • Better Business Bureau Flags Novartis Advertising for Kisqali

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing